Skip to main content

Drug-Induced Nephrotoxicity!

 DRUG-INDUCED NEPHROTOXICITY

  • Drug-Induced Nephrotoxicity is increasingly recognized as a significant contributor to kidney disease including Acute Kidney Injury (KI) and chronic kidney disease (CKD).
  • Nephrotoxicity has a wide spectrum, reflecting damage to different nephron segments based upon individual drug-mechanisms.


1. ACE-INHIBITORS:

  • ACE-Inhibitors are frequently associated with Proteinuria and Renal Insufficiency.
  • The prevalence of Proteinuria in Captopril treated patient is estimated to be 1%.
  • The risk of Renal Insufficiency is greater with long-acting ACE Inhibitors such as Lisinopril or Enalapril than with Captopril.
  • Immune complex glomerulopathy is a major contribute to ACE Inhibitor nephrotoxicity.
  • Predisposing factors include:

  1. Hyponatremia
  2. Diuretic therapy
  3. Pre-existing renal impairment
  4. Congestive Heart Failure (CHF)
  5. Diabetes Mellitus

  • Recovery of renal function usually follows ACE-Inhibitor discontinuation.


2. CEPHLOSPORIN:

  • The cephalosporin antibiotics are capable of producing rare Interstitial Nephritis similar to Penicillin's.
  • Increase in BUN and Cr(s) occur occasionally.
  • Nephrotoxicity of newer drugs is minimal compared with older such as Cephalothin.


3. DIURETICS(THIAZIDE):

  • Occasional cases of Interstitial Nephritis have been reported, which might be the result of hypersensitivity reaction.
  • Lomg-term use of diuretics increases the risk of Renal cell carcinoma, especially in women.


4. NSAIDs:

  • NSAIDs including COX-2 Inhibitors can reduce Cr (Cl) and produce renal insufficiency as a result of renal circulatory changes caused by inhibition of PG synthesis. These effects are usually reversible.
  • The prevalence is usually 1%.
  • Predisposing factors include:

  1. Old age
  2. Preexisting renal impairment
  3. Hypotension
  4. CHF
  5. Hepatic cirrhosis

  • Fenoprofen is the NSAID most commonly associated with interstitial nephritis and nephrotic syndrome.


5. OMEPRAZOLE:

  • Interstitial nephritis occurs rarely during omeprazole therapy.
  • At least 13 cases were published; 10 with positive biopsies; 5 cases were rechallenged with recurrence of interstitial nephritis in all.
  • Onset is usually after 2 weeks to 6 months of Omeprazole therapy.


Labels:

Comments

Post a Comment

Popular posts from this blog

General Mechanism of Actions of INSULIN.

GENERAL MECHANISM OF ACTION OF INSULIN AND RELATE HORMONES The body's main fuel is Glucose. Glucose is stored in the liver and muscles as Glycogen.  Excess glucose is stored in the adipose tissues which yield fatty acids via lipolysis. In the fasting state, free fatty acids supply much of the energy needs of the body except for the CNS which requires Glucose to function normally. Proteins can also be converted to glucose via gluconeogenesis. RELEASE OF INSULIN AND GLUCAGON Insulin and Glucagon are produced in the pancreas by the Islets of Langerhans . Beta cells   make up 70%-90% of the Islets and produce Insulin and Amylin while the a-cells   produce glucagon. The main function of insulin is to decrease blood glucose levels. Glucagon, along with other counter-regulatory hormones such as growth factor, cortisol, and Epinephrine, increases Blood glucose levels.  The opposing actions of Glucagon and Insulin along with other counter-regulatory hormones maintain a norma...
Post a Comment
Read more

Diabetes Mellitus: Its Goals Of Therapy!

  GOAL OF THERPY The goals of treatment of DM includes; Reducing, controlling and managing long-term microvascular, macrovascular and neuropaathic complications. Preserving beta cell function. Preventing acute complications from increased Blood glucosel level. Minimizing hypoglycemic episodes. Maintaining patient quality of life. --Two landmark trials, THE DIABETES CONTROL AND COMPLICATION TRIAL (DCCT) and THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY(UKPDS), showed that lowering blood glucose levels decreased the risk of developing chronic complications. --A near normal blood glucose level can be achieved with appropriate patient education , lifestyle modification and medications . --Proper care of DM requires goal setting and assessment for glycemic control , self-monitoring of blood glucose (SMBG) monitoring of blood glucose pressure , and lipid levels , regular monitoring for the development of complications , dietary and exercise lifestyle modifications and proper medicatio...
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-5...
Post a Comment
Read more